Holen Sie sich die Stockscreener-App
23.33
0.04%
-0.01
Handel nachbörslich:
23.24
-0.09
-0.39%
Assembly Biosciences Inc Aktie (ASMB) Neueste Nachrichten
ASMB Maintained by Mizuho -- Price Target Raised to $45 - GuruFocus
Assembly Biosciences eyes Gilead HSV plan as ABI-6250 liver pipeline expands - MSN
ASMB SEC FilingsAssembly Bioscie 10-K, 10-Q, 8-K Forms - Stock Titan
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead - MarketBeat
(ASMB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Assembly Biosciences Expands Equity Plans, Reelects Board - TipRanks
Assembly Biosciences (ASMB) CMO awarded 14,000-share RSU-based stock grant - Stock Titan
Assembly Biosciences (ASMB) CMO awarded 14,000 restricted stock units - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) awards 8,000 stock options to director McHutchison - Stock Titan
Assembly Biosciences (ASMB) director receives grant of 8,000 stock options - Stock Titan
Director at Assembly Biosciences (ASMB) receives grant of 8,000 stock options - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) director receives 8,000 stock options grant - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) director receives grant of 8,000 stock options - Stock Titan
Director at Assembly Biosciences (NASDAQ: ASMB) receives 8,000 options - Stock Titan
Assembly Biosciences (NASDAQ: ASMB) PFO awarded 3,500 RSUs - Stock Titan
Assembly Biosciences (ASMB) CSO granted 14,000 RSUs tied to plan amendment - Stock Titan
Assembly Biosciences (ASMB) CEO receives 50,750 RSUs in equity grant - Stock Titan
Assembly Biosciences (ASMB) shareholders back directors, equity plan and ESPP share hikes - Stock Titan
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands - Yahoo Finance
Assembly Biosciences synthesizes new anti-cytomegalovirus agents - BioWorld News
Gilead Sciences, Inc. Acquires Significant Stake in Assembly Biosciences Inc. - GuruFocus
Assembly Biosciences Announces Upcoming Investor Conference Presentations - The Manila Times
ASMB Reiterated by Guggenheim -- Price Target Maintained at $43 - GuruFocus
Biotech Assembly Bio set for June Jefferies, Goldman investor chats - Stock Titan
Assembly Biosciences (ASMB) Holds Steady Near Resistance as Biotech Sector WatchesSector ETF Flow - The Legal Advocate
How (ASMB) Movements Inform Risk Allocation Models - Stock Traders Daily
Gilead boosts Assembly Biosciences (NASDAQ: ASMB) ownership to 25.1% of shares - Stock Titan
Gilead adds Assembly Biosciences (ASMB) shares through new stock grant - Stock Titan
Assembly Biosciences (ASMB) Declines 4.7% as Stock Tests Key Support Near $26PCR Moving Average - newsline.com
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - The Manila Times
Assembly Biosciences closes $115 million stock offering - Investing.com UK
Assembly Biosciences closes $115 million stock offering By Investing.com - Investing.com South Africa
Assembly Biosciences Completes Significant Equity Offering Financing - TipRanks
Assembly Biosciences (ASMB) completes $115M stock and pre-funded warrant sale - Stock Titan
Assembly Bio raises $115M for viral and liver drug clinical work - Stock Titan
Assembly Biosciences Surges 6.9% as Buyers Defend Key Support Level (ASMB)High Dividend Factor - The Legal Advocate
Assembly Biosciences prices $100M equity offering - MSN
Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday - Sahm
Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC - TradingView
Assembly Biosciences (NASDAQ: ASMB) raises ~$93M; 3.36M shares, 415K pre-funded warrants - Stock Titan
Assembly Biosciences (ASMB) Expands Clinical Focus on Liver Dise - GuruFocus
Assembly Biosciences (ASMB) Prices $100M Offering to Support Cli - GuruFocus
Assembly Biosciences (NASDAQ: ASMB) launches stock and pre-funded warrant offering - Stock Titan
Assembly Biosciences prices $100 million stock offering at $26.50 - Investing.com UK
Assembly Biosciences Expands ABI-6250 Clinical Development to Target Cholestatic Liver Diseases Including PBC and PSC - Minichart
Assembly Biosciences expands ABI-6250 development to liver diseases By Investing.com - Investing.com Nigeria
Assembly Biosciences expands ABI-6250 development to liver diseases - Investing.com UK
Assembly Biosciences prices $100 million stock offering at $26.50 By Investing.com - Investing.com South Africa
Assembly Biosciences prices $100 million offering - The Pharma Letter
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):